Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Tveit KM, et al. Among authors: hofsli e. J Clin Oncol. 2012 May 20;30(15):1755-62. doi: 10.1200/JCO.2011.38.0915. Epub 2012 Apr 2. J Clin Oncol. 2012. PMID: 22473155 Clinical Trial.
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Sorbye H, et al. Among authors: hofsli e. Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11. Ann Oncol. 2013. PMID: 22967994 Free article.
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P. Winther SB, et al. Among authors: hofsli e. Lancet Gastroenterol Hepatol. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X. Epub 2019 Mar 7. Lancet Gastroenterol Hepatol. 2019. PMID: 30852136 Clinical Trial.
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.
Liposits G, Eshøj HR, Möller S, Winther SB, Skuladottir H, Ryg J, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Österlund P, Glimelius B, Sorbye H, Pfeiffer P. Liposits G, et al. Among authors: hofsli e. Cancers (Basel). 2021 May 26;13(11):2604. doi: 10.3390/cancers13112604. Cancers (Basel). 2021. PMID: 34073363 Free PMC article.
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
Larsen SG, Goscinski MA, Dueland S, Steigen SE, Hofsli E, Torgunrud A, Lund-Iversen M, Dagenborg VJ, Flatmark K, Sorbye H. Larsen SG, et al. Among authors: hofsli e. Br J Cancer. 2022 Mar;126(5):726-735. doi: 10.1038/s41416-021-01620-6. Epub 2021 Dec 9. Br J Cancer. 2022. PMID: 34887523 Free PMC article.
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer.
Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH. Meltzer S, et al. Among authors: hofsli e. Br J Cancer. 2022 Dec;127(12):2227-2233. doi: 10.1038/s41416-022-02004-0. Epub 2022 Oct 13. Br J Cancer. 2022. PMID: 36229579 Free PMC article. Clinical Trial.
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.
Liposits G, Skuladottir H, Ryg J, Winther SB, Möller S, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Osterlund P, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P. Liposits G, et al. Among authors: hofsli e. J Clin Med. 2022 Sep 23;11(19):5603. doi: 10.3390/jcm11195603. J Clin Med. 2022. PMID: 36233472 Free PMC article.
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study.
Liposits G, Ryg J, Skuladottir H, Winther SB, Möller S, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Osterlund P, Glimelius B, Sorbye H, Pfeiffer P. Liposits G, et al. Among authors: hofsli e. J Geriatr Oncol. 2023 Jan;14(1):101408. doi: 10.1016/j.jgo.2022.11.007. Epub 2022 Dec 6. J Geriatr Oncol. 2023. PMID: 36494261 Free article. Clinical Trial.
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study.
Liposits G, Winther SB, Ryg J, Skuladottir H, Möller S, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Osterlund P, Glimelius B, Sorbye H, Pfeiffer P. Liposits G, et al. Among authors: hofsli e. J Geriatr Oncol. 2024 Mar;15(2):101632. doi: 10.1016/j.jgo.2023.101632. Epub 2023 Sep 18. J Geriatr Oncol. 2024. PMID: 37730481 Free article. No abstract available.
52 results